Show simple item record

dc.contributor.author Stein DJ
dc.contributor.author Khoo JP
dc.contributor.author Ahokas A
dc.contributor.author Jarema M
dc.contributor.author Van Ameringen M
dc.contributor.author Vavrusova L
dc.contributor.author Hoschl C
dc.contributor.author Bauer M
dc.contributor.author Bitter, István
dc.contributor.author Mosolov SN
dc.contributor.author Olivier V
dc.contributor.author Matharan S
dc.contributor.author Picarel-Blanchot F
dc.contributor.author de Bodinat C
dc.date.accessioned 2018-09-21T06:57:00Z
dc.date.available 2018-09-21T06:57:00Z
dc.date.issued 2018
dc.identifier.citation pagination=970-979; journalVolume=28; journalIssueNumber=8; journalTitle=EUROPEAN NEUROPSYCHOPHARMACOLOGY;
dc.identifier.uri http://repo.lib.semmelweis.hu//handle/123456789/6493
dc.identifier.uri doi:10.1016/j.euroneuro.2018.05.006
dc.description.abstract Treatment of severely symptomatic patients with generalized anxiety disorder (GAD) raises particular concerns for clinicians. This 12-week double-blind study evaluated the efficacy of agomelatine (25-50 mg/day) in the treatment of patients with severe GAD, using escitalopram (10-20 mg) as active comparator. The primary outcome measure was the change from baseline of the total score on the Hamilton Anxiety scale (HAM-A) at week 12. Secondary outcome measures included rate of response to treatment (at least 50% score reduction from baseline) in the HAM-A psychic and somatic anxiety sub-scores, Clinical Global Impression severity and change scores, the Toronto Hospital Alertness Test, the Snaith-Hamilton Pleasure Scale, and the Leeds Sleep Evaluation Questionnaire Scores. Sixty one clinical centers (Australia, Canada, Czech Republic, Finland, Germany, Hungary, Poland, Russia, Slovakia) participated from April 2013 to February 2015. Patient characteristics and demographic data were comparable between treatment groups. Both treatments were associated with a clinically significant decrease in HAM-A total score at week 12; the non-inferiority of agomelatine versus escitalopram was not demonstrated (E(SE) = -0.91(0.69), 95% CI = [-2.26, 0.44], p = 0.195). At week 12, the response rate was 60.9% in the agomelatine group, and 64.8% in the escitalopram group. In both treatment arms, HAM-A psychic and somatic anxiety scores decreased, alertness and sleep parameters improved, and ability to experience pleasure increased. In these secondary outcome measures, there were no significant differences between the treatment groups. Agomelatine was well-tolerated, with a lower incidence of adverse events than escitalopram. Agomelatine and escitalopram are efficacious in treating GAD patients with severe symptoms. (c) 2018 Elsevier B.V. and ECNP. All rights reserved.
dc.relation.ispartof urn:issn:0924-977X
dc.title 12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder
dc.type Journal Article
dc.date.updated 2018-09-20T11:15:45Z
dc.language.rfc3066 en
dc.identifier.mtmt 3408408
dc.identifier.wos 000441875900009
dc.identifier.pubmed 30135032
dc.contributor.department SE/AOK/K/Pszichiátriai és Pszichoterápiás Klinika
dc.contributor.institution Semmelweis Egyetem


Files in this item

xmlui.dri2xhtml.METS-1.0.onlyFromAllowedIP

View/Open

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account